Alzinova AB (publ)
STO: ALZ.ST0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Stockholm Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Tord Labuda
- Employees
- 5
- Headquarters
- Mölndal, Sweden
- IPO year
- 2015
- Market cap
- SEK 42.6M
- Website
- https://www.alzinova.com
Loading ALZ…
Loading profile data…Frequently asked questions about ALZ
What does Alzinova AB (publ) (ALZ.ST) do?
Alzinova AB (publ), a biopharma company, engages in the development of an active immunotherapy for the treatment of Alzheimer's disease in Sweden. Its lead candidate is ALZ-101, an oligomer-specific vaccine for the treatment of Alzheimer's disease; and ALZ-201, a monoclonal antibody that is used for the treatment of toxic Aß oligomers. The compa...
Where does ALZ.ST trade?
Alzinova AB (publ) (ALZ.ST) trades on the Stockholm Stock Exchange.
What sector is ALZ.ST in?
Alzinova AB (publ) (ALZ.ST) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Alzinova AB (publ)?
Tord Labuda is the chief executive officer of Alzinova AB (publ) (ALZ.ST).
Where is Alzinova AB (publ) headquartered?
Alzinova AB (publ) is headquartered in Sweden.
Does ALZ.ST pay a dividend?
Alzinova AB (publ) (ALZ.ST) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did ALZ.ST go public?
Alzinova AB (publ) (ALZ.ST) completed its initial public offering in 2015.